Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 3/20 | 0.66 |
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 0.66 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.48 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501152 | 0.90 | HTR1D (0.80) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6500062 | 0.83 | HTR1D (0.74) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6502864 | 0.82 | HTR1D (0.70) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6487377 | 0.81 | HTR1D (0.81) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6488427 | 0.81 | HTR1D (0.81) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6498021 | 0.81 | HTR1D (0.81) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6488322 | 0.81 | HTR1D (0.81) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6488685 | 0.81 | HTR1D (0.81) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6498408 | 0.81 | HTR1D (0.81) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 | |
| SCHEMBL6490991 | 0.80 | HTR1D (0.80) | HTR1DHTR1BHTR2AMCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | HTR1D 1697/4885HTR1B 1495/4885HTR2A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.